메뉴 건너뛰기




Volumn 200, Issue 3, 2009, Pages 390-398

Ciprofloxacin dosage and emergence of resistance in human commensal bacteria

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; NALIDIXIC ACID;

EID: 67650675457     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/600122     Document Type: Article
Times cited : (103)

References (35)
  • 1
    • 0036360546 scopus 로고    scopus 로고
    • Evolution and spread of antibiotic resistance
    • Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med 2002; 252:91-106.
    • (2002) J Intern Med , vol.252 , pp. 91-106
    • Normark, B.H.1    Normark, S.2
  • 2
    • 0035038683 scopus 로고    scopus 로고
    • Emerging mechanisms of fluoroquinolone resistance
    • Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
    • (2001) Emerg Infect Dis , vol.7 , pp. 337-341
    • Hooper, D.C.1
  • 3
    • 0033595136 scopus 로고    scopus 로고
    • Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    • Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-9.
    • (1999) N Engl J Med , vol.341 , pp. 233-239
    • Chen, D.K.1    McGeer, A.2    de Azavedo, J.C.3    Low, D.E.4
  • 4
    • 0141924871 scopus 로고    scopus 로고
    • Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections
    • Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-32.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 3222-3232
    • Komp Lindgren, P.1    Karlsson, A.2    Hughes, D.3
  • 5
    • 25444451566 scopus 로고    scopus 로고
    • Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: The role of inadequate empirical antibiotic therapy
    • Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: The role of inadequate empirical antibiotic therapy. Clin Infect Dis 2005; 41:923-9.
    • (2005) Clin Infect Dis , vol.41 , pp. 923-929
    • Lautenbach, E.1    Metlay, J.P.2    Bilker, W.B.3    Edelstein, P.H.4    Fishman, N.O.5
  • 6
    • 0037035122 scopus 로고    scopus 로고
    • Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia
    • Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-50.
    • (2002) N Engl J Med , vol.346 , pp. 747-750
    • Davidson, R.1    Cavalcanti, R.2    Brunton, J.L.3
  • 7
    • 0033864273 scopus 로고    scopus 로고
    • Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae
    • Varon E, Gutmann L. Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae. Res Microbiol 2000; 151:471-3.
    • (2000) Res Microbiol , vol.151 , pp. 471-473
    • Varon, E.1    Gutmann, L.2
  • 8
    • 4043058319 scopus 로고    scopus 로고
    • Commensal flora may play key role in spreading antibiotic resistance
    • Andremont A. Commensal flora may play key role in spreading antibiotic resistance. ASM News 2003; 69:601-7.
    • (2003) ASM News , vol.69 , pp. 601-607
    • Andremont, A.1
  • 9
    • 0031016452 scopus 로고    scopus 로고
    • Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis
    • Hoiby N, Jarlov JO, Kemp M, et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349:167-9.
    • (1997) Lancet , vol.349 , pp. 167-169
    • Hoiby, N.1    Jarlov, J.O.2    Kemp, M.3
  • 11
    • 0032541786 scopus 로고    scopus 로고
    • Fluoroquinolone resistance: Overuse of fluoroquinolones in human and veterinary medicine can breed resistance
    • Piddock LJ. Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance. BMJ 1998; 317:1029-30.
    • (1998) BMJ , vol.317 , pp. 1029-1030
    • Piddock, L.J.1
  • 12
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic parameters: Rationale for antibacterial dosing in mice and men
    • Craig WA. Pharmacokinetic-pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998; 26: 1-12.
    • (1998) Clin Infect Dis , vol.26 , pp. 1-12
    • Craig, W.A.1
  • 13
    • 33845696211 scopus 로고    scopus 로고
    • Pharmacokineticspharmacodynamics of antibiotic therapy: It's not just for mice anymore
    • Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokineticspharmacodynamics of antibiotic therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
    • (2007) Clin Infect Dis , vol.44 , pp. 79-86
    • Ambrose, P.G.1    Bhavnani, S.M.2    Rubino, C.M.3
  • 14
    • 0035884924 scopus 로고    scopus 로고
    • Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies
    • Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33(Suppl 3):S147-56.
    • (2001) Clin Infect Dis , vol.33 , Issue.SUPPL. 3
    • Zhao, X.1    Drlica, K.2
  • 15
    • 0032515386 scopus 로고    scopus 로고
    • Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
    • Preston SL, Drusano G, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9.
    • (1998) JAMA , vol.279 , pp. 125-129
    • Preston, S.L.1    Drusano, G.2    Berman, A.L.3
  • 17
    • 0034812780 scopus 로고    scopus 로고
    • Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
    • Ambrose PG, Grasela DM, Grasela TH, Passarel J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45:2793-7.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 2793-2797
    • Ambrose, P.G.1    Grasela, D.M.2    Grasela, T.H.3    Passarel, J.4    Mayer, H.B.5    Pierce, P.F.6
  • 18
    • 2442549489 scopus 로고    scopus 로고
    • Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
    • Drusano G, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189:1590-7.
    • (2004) J Infect Dis , vol.189 , pp. 1590-1597
    • Drusano, G.1    Preston, S.L.2    Fowler, C.3    Corrado, M.4    Weisinger, B.5    Kahn, J.6
  • 19
    • 34548265066 scopus 로고    scopus 로고
    • Optimizing drug exposure to minimize selection of antibiotic resistance
    • Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007; 45:S129-36.
    • (2007) Clin Infect Dis , vol.45
    • Olofsson, S.K.1    Cars, O.2
  • 20
    • 0038778639 scopus 로고    scopus 로고
    • Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin/clavulanic acid treatments
    • Crémieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin/clavulanic acid treatments. Antimicrob Agents Chemother 2003; 47:2030-5.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 2030-2035
    • Crémieux, A.C.1    Muller-Serieys, C.2    Panhard, X.3
  • 21
    • 84855452587 scopus 로고    scopus 로고
    • Available at:, Accessed 21 June 2009
    • Comité de l'Antibiogramme de la Société Française de Microbiologie. Communiqué 2009. Available at: http://www.sfm.asso.fr/publi/general .php?pa = l. Accessed 21 June 2009.
    • (2009) Communiqué
  • 22
    • 0035139520 scopus 로고    scopus 로고
    • Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae
    • Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-8.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 433-438
    • Blondeau, J.M.1    Zhao, X.2    Hansen, G.3    Drlica, K.4
  • 23
    • 0345550450 scopus 로고    scopus 로고
    • Update of practice guidelines for the management of communityacquired pneumonia in immunocompetent adults
    • Mandeli LA, Bartlett JG, Dowell SF, File MF Jr, Musher DM, Whitney C. Update of practice guidelines for the management of communityacquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
    • (2003) Clin Infect Dis , vol.37 , pp. 1405-1433
    • Mandeli, L.A.1    Bartlett, J.G.2    Dowell, S.F.3    File Jr, M.F.4    Musher, D.M.5    Whitney, C.6
  • 25
    • 0028817847 scopus 로고
    • Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
    • Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995; 39:2635-40.
    • (1995) Antimicrob Agents Chemother , vol.39 , pp. 2635-2640
    • Nakashima, M.1    Uematsu, T.2    Kosuge, K.3
  • 26
    • 0035180109 scopus 로고    scopus 로고
    • Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis
    • Montgomery MJ, Beringer PM, Aminimanizani A, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:3468-3473.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 3468-3473
    • Montgomery, M.J.1    Beringer, P.M.2    Aminimanizani, A.3
  • 27
    • 0036896404 scopus 로고    scopus 로고
    • Target site concentrations of ciprofloxacin after single intravenous and oral doses
    • Brunner M, Stabeta H, Moller JG, et al. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 2002; 46:3724-30.
    • (2002) Antimicrob Agents Chemother , vol.46 , pp. 3724-3730
    • Brunner, M.1    Stabeta, H.2    Moller, J.G.3
  • 28
    • 0036239477 scopus 로고    scopus 로고
    • Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: A comparison of two dosages
    • Debon R, Breilh D, Boselli E, et al. Pharmacokinetic parameters of ciprofloxacin (500 mg/5 mL) oral suspension in critically ill patients with severe bacterial pneumonia: a comparison of two dosages. J Chemother 2002; 14:175-80.
    • (2002) J Chemother , vol.14 , pp. 175-180
    • Debon, R.1    Breilh, D.2    Boselli, E.3
  • 29
    • 0030067792 scopus 로고    scopus 로고
    • Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis
    • Carratala J, Fernandez-Sevilla A, Tubau F, Domínguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40:503-5.
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 503-505
    • Carratala, J.1    Fernandez-Sevilla, A.2    Tubau, F.3    Domínguez, M.A.4    Gudiol, F.5
  • 30
    • 0032837575 scopus 로고    scopus 로고
    • Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis
    • Perea S, Hidalgo M, Arcediano A, et al. Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J Antimicrob Chemother 1999; 44:117-20.
    • (1999) J Antimicrob Chemother , vol.44 , pp. 117-120
    • Perea, S.1    Hidalgo, M.2    Arcediano, A.3
  • 31
    • 0028121079 scopus 로고
    • Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis
    • Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38:340-4.
    • (1994) Antimicrob Agents Chemother , vol.38 , pp. 340-344
    • Dupeyron, C.1    Mangeney, N.2    Sedrati, L.3    Campillo, B.4    Fouet, P.5    Leluan, G.6
  • 32
    • 0031940776 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
    • Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 521-527
    • Thomas, J.K.1    Forrest, A.2    Bhavnani, S.M.3
  • 33
    • 0035468838 scopus 로고    scopus 로고
    • Effect of antibiotic agents on the ecological balance of human microflora
    • Sullivan A, Edlund C, Nord CE. Effect of antibiotic agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1:101-14.
    • (2001) Lancet Infect Dis , vol.1 , pp. 101-114
    • Sullivan, A.1    Edlund, C.2    Nord, C.E.3
  • 34
    • 0025123303 scopus 로고
    • Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers
    • Pecquet S, Ravoire S, Andremont A. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J Antimicrob Chemother 1990; 26:125-9.
    • (1990) J Antimicrob Chemother , vol.26 , pp. 125-129
    • Pecquet, S.1    Ravoire, S.2    Andremont, A.3
  • 35
    • 33745920513 scopus 로고    scopus 로고
    • Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae
    • Prudhomme M, Attaiech L, Sanchez G, Martin B, Claverys JP. Antibiotic stress induces genetic transformability in the human pathogen Streptococcus pneumoniae. Science 2006; 313:89-92.
    • (2006) Science , vol.313 , pp. 89-92
    • Prudhomme, M.1    Attaiech, L.2    Sanchez, G.3    Martin, B.4    Claverys, J.P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.